Browsing: HRHuman

Support

119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)

By 0

BackgroundMONALEESA-3 reported statistically significant overall survival (OS) benefits with ribociclib plus fulvestrant, which were maintained with extended follow-up. Patients with…